Rotterdam

• CLEOPATTRA: A research study to look at the effects of treatment with a medicine called coramitug (NNC6019-0001) in people with heart failur … Recruiting
  2024-518899-31-00 5 2025-12-19 Variant or wild-type transthyretin (TTR) amyloid cardiomyopathy
• STOP-PKD: SGLT2-inhibition to improve Prognosis in Polycystic Kidney Disease Recruiting
  2025-521276-59-00 5 2025-12-16 Autosomal dominant polycystic kidney disease (ADPKD)
• Adjuvant chemotherapy for prevention of recurrence in patients with detectable ctDNA after surgery in high-riskrectal cancer. Recruiting
  2024-517700-12-00 5 2025-12-10 Rectal cancer
• Phase 2a Study of VX-407 in Subjects with ADPKD Who Have a Subset of PKD1 Gene Variants Recruiting
  2024-517393-13-00 4 2025-12-02 Autosomal Dominant Polycystic Kidney Disease (ADPKD)
• Dato-DXd plus Carboplatin or Cisplatin versus Gemcitabine plus Carboplatin or Cisplatin in Previously Treated la/mUC. Recruiting
  2024-516906-47-00 10 2025-11-28 Locally Advanced or Metastatic Urothelial Carcinoma
• A study to investigate airway inflammation with dupilumab subcutaneously in participants aged ≥40 to ≤85 years with chronic obstructive pulm … Recruiting
  2025-521268-37-00 6 2025-11-25 Respiratory tract diseases
• A first-in-human study to learn how safe BAY 3713372 is and how it works in participants with MTAP-deleted solid tumors Recruiting
  2025-520623-24-00 7 2025-11-19 MTAP-deleted Solid Tumors
• T3-4-Hypo trial Recruiting
  2024-513883-24-00 5 2025-11-02 Hypothyroidism Triiodothyronine Quality of Life Persistant complaints
• the EMPOWER Study Recruiting
  2023-508610-42-00 4 2025-10-17 Hyponatremia
• ASPIRING Recruiting
  2024-516188-10-00 6 2025-10-07 Intracerebral haemorrhage
• The efficacy and safety of rilzabrutinib in participants aged 10 to 65 years with sickle-cell disease Recruiting
  2024-518645-17-00 5 2025-10-07 Blood and lymphatic diseases
• A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o … Recruiting
  2023-508056-19-00 5 2025-10-02 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Proficient (pMMR), P
• A clinical study of MK-7240 for the treatment of Crohn’s disease (MK-7240-008) Recruiting
  2024-518296-56-00 5 2025-09-29 Crohn’s Disease
• Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting
  2023-508057-19-00 5 2025-09-23 Advanced HER2-expressing Biliary Tract Cancer
• Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obe … Recruiting
  2024-520209-38-00 5 2025-09-19 Obesity or Overweight
• Open-label Study of ELA026 in Participants with sHLH (short title) Recruiting
  2025-520624-25-00 10 2025-09-19 Secondary Hemophagocytic Lymphohistiocytosis (sHLH)
• Selective Treatment of Oral Povorcitinib Long-Term Rollover Study (STOP-LTR) Recruiting
  2024-520107-12-00 5 2025-09-03 Hidradenitis Suppurativa // Prurigo Nodularis // Vitiligo
• The AIRTIVITY TM Study: A study to find out whether BI 1291583 helps people with bronchiectasis Recruiting
  2024-518589-29-00 5 2025-08-21 Bronchiectasis
• A study to investigate the safety and efficacy of mRNA-3927 in participants with genetically confirmed propionic acidemia Recruiting
  2022-502910-10-00 7 2025-08-11 Propionic Acidemia
• A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting
  2024-512753-24-00 5 2025-08-05 Acute Myeloid Leukemia (AML)
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• Long-term safety and efficacy study of riliprubart in participants with CIDP Recruiting
  2024-517032-22-00 5 2025-06-10 Immune system diseases.
• A Study to assess safety and effectiveness of Emicizumab in Patients with Type 3 Von Willebrand Disease Recruiting
  2024-515622-80-00 5 2025-06-04 Type 3 Von Willebrand Disease
• SUPRAME - ACTengine® IMA203 vs. investigator’s choice of treatment in previously treated, unresectable or metastatic cutaneous melanoma Recruiting
  2024-517062-42-00 5 2025-05-02 melanoma, cutaneous malignant

Showing 97–120 of 818 trials